2025-09-11 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the provided data.

**Report on Eli Lilly and Co. (LLY)**

**0. Executive Summary**

Eli Lilly (LLY) has significantly outperformed the S&P 500 (VOO) over the tracked period. Recent news and analyst opinions are generally positive, but some market indicators suggest caution. Revenue and profitability metrics are strong, showcasing solid financial health.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** LLY
*   **Company:** Eli Lilly and Co. (A leading global pharmaceutical company)
*   **LLY Cumulative Return:** 227.84%
*   **VOO Cumulative Return:** 39.61%
*   **Spread:**
    *   Current Spread: 116.3
    *   Spread Range: Max 311.6, Min -27.3
    *   Relative Spread: 42.4 (Indicates the current spread is in the lower range of its historical spread, but still significantly positive)

**Analysis:** LLY has substantially outperformed the S&P 500. The relative spread suggests that while the outperformance is significant, it is not at its peak relative to its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| ---------- | ------ | ------ | ------- | ------ | ------ |
| 2015-2017  | 10.0%  | 56.3%  | 10.0%   | 1.0    | 76.1   |
| 2016-2018  | 39.0%  | 58.6%  | 39.0%   | 1.0    | 104.3  |
| 2017-2019  | 50.0%  | 58.6%  | 50.0%   | 1.0    | 118.5  |
| 2018-2020  | 52.0%  | 58.6%  | 52.0%   | 1.0    | 152.2  |
| 2019-2021  | 106.0% | 60.6%  | 105.0%  | -0.0   | 248.9  |
| 2020-2022  | 98.0%  | 64.8%  | 109.0%  | -0.0   | 329.7  |
| 2021-2023  | 133.0% | 64.8%  | 123.0%  | -0.0   | 525.4  |
| 2022-2024  | 150.0% | 72.2%  | 120.0%  | -0.0   | 695.8  |
| 2023-2025  | 81.0%  | 76.8%  | 35.0%   | 0.0    | 676.5  |

**Analysis:**

*   **CAGR:**  Shows strong annual growth, particularly in recent years.
*   **MDD:**  Maximum Drawdown indicates significant potential for losses during downturns.
*   **Alpha:** Consistently high, indicating significant outperformance compared to a benchmark.
*   **Beta:**  Recent Betas near 0 suggest the stock's price is not strongly correlated with the overall market (S&P 500). The older values were closer to 1, but have decreased to around 0.
*   **Cap(B):**  Market capitalization has grown substantially, reflecting investor confidence.

**2. Recent Price Action**

*   **Current Price:** 750.61
*   **Last-market:** Price 754.62, Previous Close 750.61, Change 0.53
*   **5-day Moving Average:** 739.44
*   **20-day Moving Average:** 713.80
*   **60-day Moving Average:** 750.94

**Analysis:** The price closed higher than the previous close (0.53 point change). The 5-day moving average is above the 20-day moving average, suggesting a short-term upward trend.  However, the price is very close to the 60-day moving average, indicating a possible consolidation or change in trend.

**3. Market Risk Indicators and Expected Return**

*   **MRI:** 0.3261 (Low Risk)
*   **RSI:** 69.81 (Approaching overbought territory)
*   **PPO:** 0.8331 (Positive, indicating an upward trend)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **Recent Relative Spread Change (20-day):** -0.7 (Indicates a short-term decrease in relative performance)
*   **Expected Return:** 220.2% (Long-term expectation of outperforming the S&P 500)

**Analysis:** The Market Risk Indicator suggests a low-risk environment. The RSI is approaching overbought levels, which could indicate a potential pullback. The PPO supports an upward trend. The negative change in relative spread over the last 20 days suggests the stock's recent performance has slightly lagged the S&P 500. The Hybrid Signal is suggesting to buy, but with caution, and invest monthly (although the investment amount is relatively low), the price change from last market is relatively low.

**4. Recent News & Significant Events**

*   **Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets (Benzinga):**  Highlights both the potential and financial challenges related to weight-loss drugs.
*   **Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales. (Barrons.com):**  Potential regulatory changes could impact pharmaceutical sales.
*   **Rate of employers covering weight-loss drugs is flat, Cigna says (Reuters):**  Suggests that employer coverage may not be increasing as quickly as expected, potentially limiting market growth for related drugs.
*   **Eli Lilly (LLY) Unveils Lilly TuneLab AI Platform With US$1 Billion Data Investment (Simply Wall St.):**  Positive news showcasing investment in AI and data analytics.
*   **Ascletis’ GLP-1RA shows promise with quarterly dosing schedule (Clinical Trials Arena):**  Highlights competition in the GLP-1 receptor agonist space.
*   **5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds (Zacks):**  Positive signal that LLY is considered a strong stock in the industry.

**Analysis:** The news is mixed. The development of Lilly TuneLab is a strong positive, indicating innovation. However, regulatory risks and competition in the weight-loss drug market need to be considered.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.68)
*   **Target Price:** Average: 891.62 / High: 1190.00 / Low: 650.00

**Analysis:** Analysts generally have a positive outlook on LLY, with a "Buy" consensus and a significantly higher average target price than the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출          |
| ---------- | ------ | ------------- |
| 2025-08-07 | 6.3    | 15.56 B$      |
| 2025-05-01 | 3.07   | 12.73 B$      |
| 2024-10-30 | 1.08   | 11.44 B$      |
| 2024-08-08 | 3.29   | 11.30 B$      |
| 2025-08-07 | 3.29   | 11.30 B$      |

**Analysis:**

*   The most recent earnings show a significant increase in both EPS and revenue, indicating strong growth.  It appears the last row in the table is a duplicate.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue  | Profit Margin |
| ------------ | -------- | ------------- |
| 2025-06-30   | $15.56B | 84.27%        |
| 2025-03-31   | $12.73B | 82.53%        |
| 2024-12-31   | $13.53B | 82.24%        |
| 2024-09-30   | $11.44B | 81.02%        |
| 2024-06-30   | $11.30B | 80.80%        |

**Capital and Profitability**

| Quarter      | Equity    | ROE       |
| ------------ | --------- | --------- |
| 2025-06-30   | $18.27B  | 30.98%    |
| 2025-03-31   | $15.76B  | 17.50%    |
| 2024-12-31   | $14.19B  | 31.07%    |
| 2024-09-30   | $14.24B  | 6.81%     |
| 2024-06-30   | $13.56B  | 21.88%    |

**Analysis:**

*   **Revenue and Profitability:** Both revenue and profit margin have been increasing, demonstrating strong financial performance.
*   **Capital and Profitability:** Equity is increasing, and ROE shows good returns, although there is some volatility.

**7. Overall Analysis**

Eli Lilly (LLY) exhibits strong financial performance, evidenced by significant outperformance compared to the S&P 500, high revenue and profit margins, and positive analyst sentiment.  The company's investment in AI and data analytics is a positive sign for future innovation. The increase from the previous close of last market activity (754.62) is a promising sign.

However, investors should be aware of the potential for increased competition in some key markets, possible regulatory changes, and the fact that the RSI is approaching overbought territory. The recent decrease in relative spread also warrants monitoring.

Overall, LLY appears to be a strong investment, but prudent risk management is always advisable.
